IE20100174A1 - Transdermal administration of peptides - Google Patents

Transdermal administration of peptides

Info

Publication number
IE20100174A1
IE20100174A1 IE20100174A IE20100174A IE20100174A1 IE 20100174 A1 IE20100174 A1 IE 20100174A1 IE 20100174 A IE20100174 A IE 20100174A IE 20100174 A IE20100174 A IE 20100174A IE 20100174 A1 IE20100174 A1 IE 20100174A1
Authority
IE
Ireland
Prior art keywords
cys
trp
lys
phe
thr
Prior art date
Application number
IE20100174A
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Patrick Bernard Deasy
Original Assignee
Trinity College Dublin
Ipsen Mfg Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity College Dublin, Ipsen Mfg Ireland Ltd filed Critical Trinity College Dublin
Priority to IE20100174A priority Critical patent/IE20100174A1/en
Priority to CN2011800157799A priority patent/CN102883735A/zh
Priority to KR1020127027694A priority patent/KR20130062275A/ko
Priority to US13/637,244 priority patent/US20130085105A1/en
Priority to EP11712680A priority patent/EP2550005A1/en
Priority to MX2012010343A priority patent/MX2012010343A/es
Priority to CA2792470A priority patent/CA2792470A1/en
Priority to AU2011231173A priority patent/AU2011231173A1/en
Priority to RU2012145278/15A priority patent/RU2012145278A/ru
Priority to BR112012022377A priority patent/BR112012022377A2/pt
Priority to JP2013500647A priority patent/JP2013523629A/ja
Priority to PCT/IE2011/000019 priority patent/WO2011117851A1/en
Publication of IE20100174A1 publication Critical patent/IE20100174A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IE20100174A 2010-03-25 2010-03-25 Transdermal administration of peptides IE20100174A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IE20100174A IE20100174A1 (en) 2010-03-25 2010-03-25 Transdermal administration of peptides
CN2011800157799A CN102883735A (zh) 2010-03-25 2011-03-23 肽的透皮给药
KR1020127027694A KR20130062275A (ko) 2010-03-25 2011-03-23 펩티드의 경피 투여
US13/637,244 US20130085105A1 (en) 2010-03-25 2011-03-23 Transdermal Administration Of Peptides
EP11712680A EP2550005A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides
MX2012010343A MX2012010343A (es) 2010-03-25 2011-03-23 Administracion transdermica de peptidos.
CA2792470A CA2792470A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides
AU2011231173A AU2011231173A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides
RU2012145278/15A RU2012145278A (ru) 2010-03-25 2011-03-23 Трансдермальное введение пептидов
BR112012022377A BR112012022377A2 (pt) 2010-03-25 2011-03-23 "administração transdérmica de peptídeos"
JP2013500647A JP2013523629A (ja) 2010-03-25 2011-03-23 ペプチドの経皮投与方法
PCT/IE2011/000019 WO2011117851A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE20100174A IE20100174A1 (en) 2010-03-25 2010-03-25 Transdermal administration of peptides

Publications (1)

Publication Number Publication Date
IE20100174A1 true IE20100174A1 (en) 2012-02-29

Family

ID=44210069

Family Applications (1)

Application Number Title Priority Date Filing Date
IE20100174A IE20100174A1 (en) 2010-03-25 2010-03-25 Transdermal administration of peptides

Country Status (12)

Country Link
US (1) US20130085105A1 (enExample)
EP (1) EP2550005A1 (enExample)
JP (1) JP2013523629A (enExample)
KR (1) KR20130062275A (enExample)
CN (1) CN102883735A (enExample)
AU (1) AU2011231173A1 (enExample)
BR (1) BR112012022377A2 (enExample)
CA (1) CA2792470A1 (enExample)
IE (1) IE20100174A1 (enExample)
MX (1) MX2012010343A (enExample)
RU (1) RU2012145278A (enExample)
WO (1) WO2011117851A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
WO2011115871A1 (en) * 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
TWI662967B (zh) * 2013-03-25 2019-06-21 日商志瑞亞新藥工業股份有限公司 食後期之胃運動亢進劑
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
KR101786914B1 (ko) * 2017-01-31 2017-11-15 주식회사 삼양사 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드
CN107226840A (zh) * 2017-05-04 2017-10-03 西安交通大学 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用
CA3076751A1 (en) * 2017-09-26 2019-04-04 Aquestive Therapeutics, Inc. Delivery pharmaceutical compositions including permeation enhancers
WO2019236603A1 (en) * 2018-06-08 2019-12-12 Saint Louis University Methods and compositions for treating decreased cognitive ability
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
DE102020130492A1 (de) * 2020-11-18 2022-05-19 Lts Lohmann Therapie-Systeme Ag. Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954975A (en) * 1972-02-17 1976-05-04 Ciba-Geigy Corporation Salts of ACTH-peptides and processes for their manufacture
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
JPH08505367A (ja) * 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
US6316414B1 (en) * 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
CA2450446A1 (en) * 2001-06-25 2003-01-03 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
WO2006040447A1 (fr) * 2004-10-07 2006-04-20 L'oreal Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
JP5231412B2 (ja) * 2006-07-11 2013-07-10 キューピーエス リミテッド ライアビリティ カンパニー ペプチドを持続的放出により送達するための薬理組成物
GB0705264D0 (en) * 2007-03-20 2007-04-25 Pliva Istrazivanje I Razvoj D Gel forming compounds
US20100196264A1 (en) * 2007-05-18 2010-08-05 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery

Also Published As

Publication number Publication date
BR112012022377A2 (pt) 2017-01-10
CN102883735A (zh) 2013-01-16
US20130085105A1 (en) 2013-04-04
KR20130062275A (ko) 2013-06-12
WO2011117851A1 (en) 2011-09-29
MX2012010343A (es) 2013-01-29
JP2013523629A (ja) 2013-06-17
EP2550005A1 (en) 2013-01-30
CA2792470A1 (en) 2011-09-29
AU2011231173A1 (en) 2012-10-18
RU2012145278A (ru) 2014-04-27

Similar Documents

Publication Publication Date Title
US20130085105A1 (en) Transdermal Administration Of Peptides
Ghigo et al. Growth hormone-releasing peptides
US5604203A (en) Analogs of peptide YY and uses thereof
TWI331922B (en) Growth hormone releasing peptides
JP2018021081A (ja) 新規のグルカゴン類似体
US20090227519A1 (en) Compounds for control of appetite
JPH0427995B2 (enExample)
US6025471A (en) Diazaspiro, azepino and azabicyclo therapeutic peptides
KR20070051948A (ko) 글루카곤 억제용 제약학적 조성물
JP2002542159A (ja) メラノコルチン受容体リガンド
JPH09507217A (ja) 成長ホルモン放出特性を持つ化合物
JP2009161546A (ja) グレリン類似体
CA2335341A1 (en) Peptide analogues of pacap
EP1616571A2 (en) Lysine containing peptides for treatment of heart disease
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
JP2000505105A (ja) ペプチドｙｙのアナログおよびその使用
Zarandi et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH)
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
SK6352001A3 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
JP2004513079A (ja) 鎮痛性ペプチドを含んでなる薬剤組成物
US7994119B2 (en) Compounds for control of appetite
HK1180959A (en) Transdermal administration of peptides
CN115873096A (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
US8846616B1 (en) Alpha-melanocyte stimulating hormone as topical anti-inflammatory agent for the treatment of allergic contact dermatitis and eczema

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)
MM9A Patent lapsed through non-payment of renewal fee